(MENAFNEditorial)
Despite growing in recent years the absolute value of the Estonian pharmaceutical market remains small and will continue to remain a marginal market in the Central and Eastern European region. Low-co st generic drugs are prevalent i n the market with doctors obliged to prescribe by international non-proprietary names (INNs) rather than branded names unless there is a specific medical reason for a branded product to be used. Despite the small size of the pharmaceuticals industry it does have a strong biotechnology sector and multinational presence i n the market is increasing. There is also potential for manufacturers to use the country as a low-cost export base rather than as a destination.
Full Report Details at
- http://www.fastmr.com/prod/965768_estonia_pharmaceuticals_healthcare_report_q2_2015.aspx?afid=101
Headline Expenditure Projections
* Pharmaceuticals: From EUR276mn (USD364mn) in 2013 to EUR292mn (USD391mn) in 2014; +5.9% in local currency terms and +7.5% in US dollar terms.
* Healthcare: EUR1.11bn (USD1.46bn) in 2013 to EUR1.16bn (USD1.55bn) in 2014; +4.3% in local currency terms and +5.9% in US dollar terms .
Risk/Reward Index
Estonia scores 52.1 out of 100 in BMI's adjusted Pharmaceutical Risk/Reward Index (RRI) tool moving up one to ninth position out of the 20 key markets covered in Central and Eastern Europe. Estonia's Industry Rewards score is still the weakest part of its pharmaceutical profile. That it scores as high as it does is mainly due to above-average scores in the urban/rural split and pensionable population. As the population ages the dominant types of disease will shift with the emergence of many more long-lasting chronic conditions cancers and degenerative illnesses. This will tip the ratio of working people to dependants towards the latter increasing the pressure on overall funding for the healthcare system.
Key Trends And Developments
In November 2014 Vectura confirmed that its partner Sandoz (Novartis) has been granted marketing authorisation by the pharmaceutical regulatory authorities in Estonia Latvia and...
The Estonia Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports focusing on the growth outlook for the prescription OTC patented drugs and generics market segments.
BMI's Estonia Pharmaceuticals & Healthcare Report provides industry professionals strategists company executives investors analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Estonia pharmaceutical and healthcare industry.
Key Benefits
* Benchmark BMI's pharmaceutical and healthcare market forecasts for Estonia to test other views - a key input for successful budgeting and strategic business planning in the Estonian pharmaceutical and healthcare market.
* Target business opportunities and risks in the Estonian pharmaceutical and healthcare sector through our reviews of latest industry trends regulatory changes and major deals projects and investments in Estonia.
* Assess the activities strategy and market position of your competitors using our company profiles (including SWOTs KPIs and latest activity) and competitive landscape tables.
Coverage
BMI Industry ViewAn at-a-glance perspective on the latest regulatory developments key forecast indicators and major corporate developments covering the prescription OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis and taken together with BMI’s political economic and business environment SWOTs it gives a complete overview of market climate.
BMI Industry Forecast ScenarioIndustry forecasts to end-2019 for all key indicators supported by explicit assumptions plus analysis of key downside risks to the main forecasts:
* Healthcare: Total healthcare expenditure (USDbn) healthcare expenditure (% of GDP) healthcare expenditure per capita (USD) hospital beds doctors and birth & mortality rates (all per ‘000 population).
* Pharmaceutical Market: Drug expenditure in USDbn % of GDP and per capita (USD).
* Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
* Generic Drug Market: Generic product sales (USDbn) generic sales (% of total sales).
* OTC Drug Market: OTC sales (USDbn & % of total sales).
* Macroeconomic Forecasts: Nominal and real GDP % real GDP growth % private consumption growth % industrial output growth % consumer price index % GDP price deflator exports imports trade balance current account balance foreign direct investment exchange rate against USD government expenditure and external debt.
BMI’s Pharmaceuticals and Healthcare Risk Reward IndexBMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry economic and demographic data points to provide indices of highest to lowest appeal to investors with each position explained.
Market SummaryA snapshot of key market characteristics including total size of the pharmaceuticals and healthcare segments growth drivers leading therapeutic areas and the competitive landscape
Industry DevelopmentsA focus on government healthcare reforms epidemiological trends mergers and acquisitions product launches market entries FDI activity R&D biotechnology clinical trials and supply chain issues.
Regulatory RegimeDetails of the industry regulatory framework and key legislation covering the licensing of new products/services pricing and reimbursements intellectual property taxation and advertising as well as analysis of the overall regulatory burden.
Competitive LandscapeThe competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector as well as the OTC generics and distribution sub-sectors.
Company Profiles*
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts we provide quick and easy access to the best competitive intelligence available. Our unbiased expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.